| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 603259.CN | WuXi AppTec Co., Ltd. Class A | 80.8 | ¤42,404 | CN |
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 67.8 | ¤12,489 | CN |
| 002653.CN | Haisco Pharmaceutical Group Co. Ltd. Cla | 69.1 | ¤8,020 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 91.3 | ¤5,577 | CN |
| 688336.CN | Sunshine Guojian Pharmaceutical (Shangha | 86.0 | ¤5,047 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300515.CN | Hunan Sundy Science and Technology Co., | 73.8 | ¤444 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 62.7 | ¤516 | CN |
| 688046.CN | GemPharmatech Co., Ltd. Class A | 64.1 | ¤522 | CN |
| 603998.CN | Hunan Fangsheng Pharmaceutical Co., Ltd. | 66.6 | ¤621 | CN |
| 300871.CN | Hvsen Biotechnology Co. Ltd. Class A | 67.1 | ¤680 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 67.8 | 21 | CN |
| 000423.CN | Dong-E-E-Jiao Co., Ltd. Class A | 71.2 | 20 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 73.8 | 10 | CN |
| 600867.CN | Tonghua Dongbao Pharmaceutical Co., Ltd. | 64.2 | 10 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 62.7 | 8 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 68.1 | 8 | CN |
| 002603.CN | Shijiazhuang Yiling Pharmaceutical Co., | 61.6 | 6 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 91.3 | 6 | CN |
| 002437.CN | Harbin Gloria Pharmaceuticals Co., Ltd. | 61.6 | 5 | CN |
| 300206.CN | Edan Instruments, Inc. Class A | 66.3 | 5 | CN |
| Average Market Cap | ¤3,751 |
| Median Market Cap | ¤1,246 |
| Avg. 3 Mo. Dollar Vol. | ¤58,014,225 |
| Avg. 3 Mo. Trading Vol. | 14,141,516 |
| Last Rebalance Date | 06/15/2026 |
| Companies Replaced | 16 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 22.2 |
| Forward P/E Ratio (12 Mo.) | 20.9 |
| Price/Book Ratio | 3.1 |
| Avg. Revenue Chg. - 3 Yr | 52.0% |
| Avg. Op. Income Chg. - 3 Yr. | 64.8% |
| Avg. EPS Growth - 3 Yr. | 19.2% |
| Avg. EPS Growth - 1 Yr. | 12.9% |
| Avg. Operating Margin | 19.1% |
| Avg. LT Debt to Total Capital | 6.5% |
| Avg. Return on Equity | 15.7% |
| Dividend Yield | 1.5% |
| China Health Care Index | 66.3 |
| China | 100.0% |
